Comprehensive molecular and immune profiling of triple-negative invasive lobular carcinoma

Authors:

Pooja Advani, Sachin Kumar Deshmukh, Sharon Wu, Jacob Andring, Joanne Xiu, Jose P. Leone, Priya Jayachandran, Stephanie L. Graff, Matthew J. Oberley, George W. Sledge Jr., Asher Chanan-Khan

Background:

  • PDZ and LIM domain protein 2 (PDLIM2) acts as tumor suppressor by downregulating NF-kB and STAT3 signaling, modulating inflammation, immune response, and cell survival.

  • Mouse models have demonstrated that downregulation of PDLIM2 leads to PD-1 immune blockade and chemotherapy resistance.

  • We characterized the genomic and immunological landscape of PDLIM2 expression in Adenocarcinoma non-small cell lung cancer (NSCLC).

Download Publication